International Journal of Gynecological Cancer

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
pp. 679-691(13)
Authors: DUFFY,; BONFRER,; KULPA,; RUSTIN,; SOLETORMOS,; TORRE,; TUXEN,; ZWIRNER,

Hormonal treatments and epithelial ovarian cancer risk
pp. 692-700(9)
Authors: AURANEN,; HIETANEN,; SALMI,; GRÉNMAN,

Positron emission tomography application for gynecologic tumors
pp. 701-709(9)
Authors: NAKAMOTO,; SAGA,; FUJII,

Angiogenesis in gynecological oncology—mechanism of tumor progression and therapeutic targets
pp. 710-726(17)
Authors: RASILA,; BURGER,; SMITH,; LEE,; VERSCHRAEGEN,

Human papillomavirus infection: biology, epidemiology, and prevention
pp. 727-746(20)
Authors: SCHEURER,; TORTOLERO-LUNA,; ADLER-STORTHZ,

Profiling of proteins associated with cisplatin resistance in ovarian cancer cells
pp. 747-754(8)
Authors: ZHU,; FUKASAWA,; FUJINOKI,; FURUNO,; INABA,; YAMAZAKI,; KAMEMORI,; KOUSAKA,; OTA,; HAYASHI,; MAEHAMA,

The contribution of spirituality and spiritual coping to anxiety and depression in women with a recent diagnosis of gynecological cancer
pp. 755-761(7)
Authors: BOSCAGLIA,; CLARKE,; JOBLING,; QUINN,

Favorable clinical behavior in young ovarian carcinoma patients: a rationale for conservative surgery?
pp. 762-769(8)
Authors: SARDI,; ANCHEZAR,; BERMUDEZ,

Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer
pp. 770-775(6)
Authors: LE,; FAUGHT,; HOPKINS,; FUNG KEE FUNG,

Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma
pp. 776-779(4)
Authors: VERGOTE,; MARQUETTE,; AMANT,; BERTELOOT,; NEVEN,

Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity
pp. 780-784(5)
Authors: KANDEL,; LOEHR,; HARTER,; TRAUT,; GNAUERT,; duBOIS,

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
pp. 785-792(8)
Authors: GORDON,; FINKLER,; EDWARDS,; GARCIA,; CROZIER,; IRWIN,; BARRETT,

Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review
pp. 793-798(6)
Authors: MITCHELL,; CARSON,; JUDSON,; DOWNS,

Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies
pp. 799-806(8)
Authors: LÊ,; SWENERTON,; ELIT,; PROVENCHER,; STUART,; LE,; LEE,; RODGERS,; POND,; HU,; OZA,

Ifosfamide-induced encephalopathy with or without using methylene blue
pp. 807-810(4)
Authors: PARK,; LEE,; HWANG,

Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy
pp. 811-816(6)
Authors: LE,; HOPKINS,; FUNG KEE FUNG,

Using logistic regression analysis in preliminary differential diagnosis of adnexal masses
pp. 817-823(7)
Authors: SZPUREK, D.; RAFAL, M.; AGATA, S.; STEFAN, S.

Brain metastases from epithelial ovarian cancer
pp. 824-829(6)
Authors: TAY, S.-K.; RAJESH, H.

Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis
pp. 830-835(6)
Authors: MANGILI,; ALETTI,; FRIGERIO,; FRANCHI,; PANACCI,; VIGANÒ,; DE MARZI,; ZANETTO,; FERRARI,

Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma
pp. 836-843(8)
Authors: GRONLUND,; DEHN,; HØGdall,; ENGELHOLM,; JØRGENSEN,; NØRGAARD-PEDERSEN,; HØGDALL,

Microvessel density in ovarian carcinoma: computer image analysis in patients with shorter and longer survival
pp. 844-849(6)
Authors: RASPOLLINI, M.R.; AMUNNI, G.; VILLANUCCI, A.; BARONI, G.; BODDI, V.; ROSSI DEGL’INNOCENTI, D.; TADDEI, G.L.

A clinically relevant orthotopic implantation nude mouse model of human epithelial ovarian cancer—based on consecutive observation
pp. 850-855(6)
Authors: YI, X.-F.; YUAN, S.-T.; LU, L.-J.; DING, J.; FENG, Y.-J.

Establishment and characterization of a human ovarian sarcomatoid carcinoma cell line BUPH:OVSC
pp. 856-865(10)
Authors: GUO, H.-F.; FENG, J.; LIU, G.; CUI, H.; YE, X.; YAO, Y.; FU, T.

The effects of ovulation induction on ovarian epithelium dysplasia scores and Ki67 expression: an experimental study on rats
pp. 866-871(6)
Authors: CORAKCI, A.; FILIZ, S.; CALISKAN, E.; DALCIK, C.; OZEREN, S.; DALCIK, H.

Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines
pp. 872-877(6)
Authors: KONG,; HUANG,; WANG,; MA,; QU,; JIANG,; YANG,; ZHANG,; CUI,

Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer
pp. 878-883(6)
Authors: CHEN,; SHEN,; LEE,; CHOW,

Aggressive locally recurrent vulvar cancer: review of cases presented to Massachusetts General Hospital 1990 to present
pp. 884-889(6)
Authors: SPIRYDA,; FULLER,; GOODMAN,

Results of radiotherapy alone in the treatment of carcinoma of uterine cervix: a retrospective analysis of 1069 patients
pp. 890-897(8)
Authors: SAIBISHKUMAR,; PATEL,; SHARMA,

Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?
pp. 898-902(5)
Authors: HAIDOPOULOS, D.; DIAKOMANOLIS, E.; RODOLAKIS, A.; VOULGARIS, Z.; VLACHOS, G.; INTSAKLIS, A.

Atypical glandular cells: improvement in cytohistologic correlation by the 2001 Bethesda system
pp. 903-910(8)
Authors: GURBUZ,; KARATEKE,; KABACA,; KIR,

Urinary incontinence in gynecological oncology patients
pp. 911-914(4)
Authors: DEL PRIORE,; TAYLOR,; ESDAILE,; MASCH,; MARTAS,; WIRTH,

A reappraisal on the management of lumbosacral plexopathies in gynecological malignancies: where do the physiatrists stand?
pp. 915-917(3)
Authors: ÖZÇAKAR, L.; KARA, M.; EROL, Ö.; KAYMAK, B.; AKINCI, A.; TAKIRAN, Ç.; AYHAN, A.

The psychosocial impact of cervical cancer among affected women and their partners
pp. 918-925(8)
Authors: deGROOT,; MAH,; FYLES,; WINTON,; GREENWOOD,; DePETRILLO,; DEVINS,

Postoperative vaginal brachytherapy alone is the treatment of choice for grade 1–2, stage IC endometrial cancer
pp. 926-931(6)
Authors: CENGIZ,; SINGH,; GRIGSBY,

Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in patients with stage I and II endometrial cancer
pp. 932-937(6)
Authors: KIM, D.-Y; KIM, M.-K; KIM, J.-H; SUH, D.-S; KIM, Y.-M; KIM, Y.-T; MOK, J.-E; NAM, J.-H

Dietary factors and endometrial cancer risk. Results of a case–control study in Mexico
pp. 938-945(8)
Authors: SALAZAR-MARTINEZ,; LAZCANO-PONCE,; SANCHEZ-ZAMORANO,; GONZALEZ-LIRA,; ESCUDERO-DE LOS RIOS,; HERNANDEZ-AVILA,

Comparison of the results of surgical treatment using laparoscopy and laparotomy in patients with endometrial cancer
pp. 946-951(6)
Authors: SOBICZEWSKI,; BIDZINSKI,; DERLATKA,; DASKA-BIDZISKA,; GMYREK,; PANEK,

Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas
pp. 952-963(12)
Authors: SAFFARI, B.; BERNSTEIN, L.; HONG, D.C.; SULLIVAN-HALLEY, J.; RUNNEBAUM, I.B.; GRILL, H.-J.; JONES, L.A.; EL-NAGGAR, A.; PRESS, M.F.

The Martius flap neovagina revisited
pp. 964-966(3)
Authors: GREEN,; ESCOBAR,; NEUBAURER,; MICHENER,; VON GRUENIGEN,

Selective vessel ligation in the pelvis: an invaluable tool in certain surgical procedures
pp. 967-973(7)
Authors: SIEUNARINE,; MOXEY,; BOYLE,; UNGAR,; LINDSAY,; DEL PRIORE,; SMITH,

Reproductive preservation for treatment of stage IA endometrial cancer in a young woman: hysteroscopic resection
pp. 974-978(5)
Authors: MAZZON,; CORRADO,; MORRICONE,; SCAMBIA,

Unusual location of ovarian mixed germ cell tumor
pp. 979-983(5)
Authors: GHAEMMAGHAMI,; AYATOLLAHI,; DANESHBODI,; AZMOODEH,

Role of adnexectomy in the surgical treatment of cervical adenocarcinoma
pp. 984-984(1)

Response to the letter of Van Calsteren et al.
pp. 985-985(1)

Role of cyclin-dependent kinase p27 in uterine carcinosarcomas
pp. 986-987(2)

Response to the letter of Caluwaerts et al.
pp. 988-988(1)

To the Editor:
pp. 989-989(1)

To the Editor:
pp. 990-990(1)

The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients
pp. 991-992(2)

Routine follow-up in cancer patients appears to be a precious ritual
pp. 993-994(2)